🟢 Ocugen is trading 6.4% up in pre-market after completing OCU400 Phase 3 enrollment

Ocugen is trading 6.35% up at $0.93 in pre-market after third-quarter results and gene-therapy progress.

• November 4 update: OCU400 Phase 3 enrollment is complete; topline data are expected in Q1 2027.
• The update also cited provisional approval in The Bahamas and a new Middle East and North Africa licensing agreement.
• Cash and investments were $84.6 million, with runway expected into 2028. Biotech’s reported 2.08% pre-market rise may be supportive, but evidence does not establish it as the primary driver.